Nextgen has started preclinical studies of the efficacy of a gene therapy drug for the treatment of androgenic alopecia. It is the expansion of indications for the use of the world's first genotherapeutic drug Neovasculgen with the mechanism of action therapeutic angiogenesis (therapeutic vascular growth).

Artgen Biotech did not extend the deadline for the placement of additional shares in the amount of 17,354,549 shares, refusing to increase the authorized capital. To finance the group's plans for 2024-2026, the company decided to use profits and capital raising in group companies. Against the background of high interest rates and undervalued stock market ass...

Artgen Biotech and the Skolkovo Foundation signed a strategic partnership agreement. Key goals of agreement: creation of a competence centre for the development of biotechnological drugs and vaccines and creation of an industrial technopark for scaling up technologies for the production of these drugs and their small-scale production.

Russian Scientific Center of Surgery named after Academician B.V. Petrovsky is conducting a clinical trial of gene-activated osteoplastic material for the treatment of patients with spine diseases. More than 200 patients have already been included in the study. A total of 300 patients will take part in the study. Gene-activated material for bone grafting was...